Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD.
about
Present and future in the treatment of diabetic kidney diseaseIndoxyl Sulfate-Review of Toxicity and Therapeutic StrategiesThe Gut as a Source of Inflammation in Chronic Kidney DiseaseReducing the costs of chronic kidney disease while delivering quality health care: a call to action.The systemic nature of CKD.Kidney disease and obesity: epidemiology, mechanisms and treatment.Gut microbiome and kidney disease: a bidirectional relationship.Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target.Dietary Metabolites and Chronic Kidney Disease.Nutrients Turned into Toxins: Microbiota Modulation of Nutrient Properties in Chronic Kidney Disease.Development and evaluation of adsorption sheet (HD safe sheet-U) using active carbon for the purpose of the preventing the contamination diffusion of urinary excreted anticancer drug.Indoxyl sulphate and kidney disease: Causes, consequences and interventions.The Role of Liver in Determining Serum Colon-Derived Uremic Solutes.Gut microbiome in chronic kidney disease.Metabolomics and renal disease.Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): A Randomized Trial.Continuous Reduction of Protein-Bound Uraemic Toxins with Improved Oxidative Stress by Using the Oral Charcoal Adsorbent AST-120 in Haemodialysis PatientsThe effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials.Tryptophan metabolism, its relation to inflammation and stress markers and association with psychological and cognitive functioning: Tasmanian Chronic Kidney Disease pilot study.The gut-kidney connection in advanced chronic kidney disease.Uremic Toxicity of Advanced Glycation End Products in CKD.Untargeted plasma and tissue metabolomics in rats with chronic kidney disease given AST-120.A Randomized, Controlled Trial of Oral Intestinal Sorbent AST-120 on Renal Function Deterioration in Patients with Advanced Renal DysfunctionEffect of renal impairment on atherosclerosis: only partially mediated by homocysteinep-Cresyl Sulfate.Sustained uremic toxin control improves renal and cardiovascular outcomes in patients with advanced renal dysfunction: post-hoc analysis of the Kremezin Study against renal disease progression in Korea.The intestine and the kidneys: a bad marriage can be hazardous.Intestinal Barrier Disturbances in Haemodialysis Patients: Mechanisms, Consequences, and Therapeutic Options.Protein-bound uremic toxins: a long overlooked culprit in cardiorenal syndrome.Indoxyl sulfate, a valuable biomarker in chronic kidney disease and dialysis.The gut-kidney axis.Vasculopathy in the setting of cardiorenal syndrome: roles of protein-bound uremic toxins.Uremic Toxicity and Bone in CKD.Constipation and Incident CKD.Gut Lactobacillus protects against the progression of renal damage by modulating the gut environment in rats.Impact of the Oral Adsorbent AST-120 on Organ-Specific Accumulation of Uremic Toxins: LC-MS/MS and MS Imaging Techniques.Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update.The uremic toxin indoxyl sulfate interferes with iron metabolism by regulating hepcidin in chronic kidney disease.Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120.
P2860
Q26864133-7F1D1E53-7E4E-400D-9237-40ADD429ABBBQ28075033-499B7C3B-7113-416F-A4BA-999F60E90EDEQ28081781-EB9E2795-84A4-4479-AC71-CE0516E5B2D2Q30234324-6466FE0B-2012-4FF6-889B-82B317BB8552Q30234695-76158BEA-AE4F-4AEB-9D70-015EC3E5CEB5Q30239002-562C8275-6B0C-47E5-891B-34641DE2DCF1Q33586234-92B8AD2B-737D-4EE7-B406-37E5EBFB97BBQ33613115-360DAF64-2FBA-4FEC-8B41-C277C953FE37Q33616732-A74D1027-D097-4832-8AD8-AF7D0346FA63Q33749467-0F7C457F-A5DA-48C1-AB8E-857089AAEA42Q33759573-2A0B84F1-0C3D-407A-9B2F-F4B933D29B8EQ35736317-CB158920-E333-4ADE-BE58-A7982AE399A6Q35741260-AA28562F-8BB1-4F49-B000-FF4DF2F00526Q35764101-4DC779B7-74BD-476F-9765-93A4F3D04487Q35778649-5AD04B49-A790-44F0-8EB8-CF15F05BE78BQ35895422-441429EC-1714-4B00-97E1-D3D04A26CBE3Q36099390-A4BEE485-EB38-4E17-9983-593C11E1B9ECQ36156898-50442683-437E-40C4-8402-34DE8B25CD2BQ36189171-F4F163AA-1C7F-49B0-A28D-DAD670CCBEA5Q36397047-39234E91-CCC3-47C0-B819-847D14836F2DQ36514906-7360A9B7-8536-4DAD-A6EB-170E801A155BQ36638243-E9CE1030-220A-4C3B-83CF-66B1DB313ED0Q36770933-004DB762-6DBE-4071-AA56-8B76F406670BQ36926923-874566E4-5BAE-476F-8DDB-9F3C4EA0DC00Q37672982-362AB1B2-01B0-4B5D-A361-E1B82C1BBBC1Q37674146-F13F1C81-12C0-4A20-A4B4-AA027A413453Q38393212-0D177D27-5353-4E17-8344-2936F96F4300Q38757951-39620A6D-4A0D-4FCC-9413-72BDD4177DD7Q38826236-1623BE7F-3939-401B-A96B-21B4B47C93F7Q38951536-CAC0D713-0043-4769-A015-7F2DA653D07FQ39009765-31225ABD-FBB8-40FA-8C96-9DB5CACBA3FAQ39243739-1FBB50DF-262C-43D5-B469-52E85430F290Q39345412-03004104-7791-4603-85FB-8AEF5B858FD9Q40364386-C46F3E00-6A61-4B48-9E27-549B0894FE8EQ46650965-6F2B948C-7626-4EF0-94DA-0D6D04798934Q47214357-D4772837-3362-40B3-952A-30640135AE6AQ47216784-F9407761-A0C6-4129-9404-2D0AB374B01CQ47851147-0AD7ED23-8150-4E1A-8D40-784F95FC9DF1Q47942386-59AFF0F5-CF47-41C7-9503-414CDEDDFF60Q48031661-B98DCB23-AA3A-4D93-B528-E9898BE6579A
P2860
Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD.
@ast
Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD.
@en
type
label
Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD.
@ast
Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD.
@en
prefLabel
Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD.
@ast
Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD.
@en
P2093
P2860
P356
P1476
Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD.
@en
P2093
Akira Kato
Eberhard Ritz
Gerald J Beck
Gerald Schulman
Kiyoshi Arita
Miho Shimizu
Tomas Berl
P2860
P304
P356
10.1681/ASN.2014010042
P577
2014-10-27T00:00:00Z